Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 141

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 141
---
2.8 million increase in cost of materials, $2.5 million of which resulted from increased revenue sample volume and $0.3 million of which was primarily related to an increase in inventory reserve expense, and a $0.4 million increase in shipping and handling expenses.

Research and Development

    Year Ended December 31,

    Change
     
    Percent of Revenue

    (in thousands, except percentages)
     
    2024

    2023

    $

    %
     
    2024

    2023

    Research and development
     
    $
    102,953

    $
    122,117

    $
    (19,164
    )
     
    (16)%

    58
    %

    72
    %

The following table presents disaggregated research and development expenses by cost classification for the periods presented: 

    Year Ended December 31,

    (in thousands)
     
    2024

    2023

    Change

    Research and development materials and allocated production laboratory expenses
     
    $
    15,844

    $
    20,243

    $
    (4,399
    )

    Personnel expenses

    62,742

    74,385

    (11,643
    )

    Allocable facilities and information technology expenses

    10,839

    11,617

    (778
    )

    Software and cloud services expenses

    4,908

    3,394

    1,514

    Depreciation and other expenses

    8,620

    12,478

    (3,858
    )

    Total
     
    $
    102,953

    $
    122,117

    $
    (19,164
    )

The $19.2 million decrease in research and development expenses was primarily attributable to an $11.6 million decrease in personnel costs and a $4.4 million decrease in laboratory materials and allocated production laboratory expenses, which was driven primarily by decreased investments in drug discovery efforts, including collaboration efforts with Genentech, and decreased investments in TCR-antigen binding development activities, partially offset by an increase in investments related to the MRD business. There was also a $3.9 million decrease in depreciation and other expenses, inclusive of a $2.6 million decrease in costs related to collaboration studies primarily related to Immune Medicine